Logistic LASSO Regression for Dietary Intakes and Breast Cancer
Overview
Affiliations
A multitude of dietary factors from dietary fat to macro and micronutrients intakes have been associated with breast cancer, yet data are still equivocal. Therefore, utilizing data from the large, multi-year, cross-sectional National Health and Nutrition Examination Survey (NHANES), we applied a novel, modern statistical shrinkage technique, logistic least absolute shrinkage and selection operator (LASSO) regression, to examine the association between dietary intakes in women, ≥50 years, with self-reported breast cancer ( = 286) compared with women without self-reported breast cancer (1144) from the 1999-2010 NHANES cycle. Logistic LASSO regression was used to examine the relationship between twenty-nine variables, including dietary variables from food, as well as well-established/known breast cancer risk factors, and to subsequently identify the most relevant variables associated with self-reported breast cancer. We observed that as the penalty factor (λ) increased in the logistic LASSO regression, well-established breast cancer risk factors, including age (β = 0.83) and parity (β = -0.05) remained in the model. For dietary macro and micronutrient intakes, only vitamin B12 (β = 0.07) was positively associated with self-reported breast cancer. Caffeine (β = -0.01) and alcohol (β = 0.03) use also continued to remain in the model. These data suggest that a diet high in vitamin B12, as well as alcohol use may be associated with self-reported breast cancer. Nonetheless, additional prospective studies should apply more recent statistical techniques to dietary data and cancer outcomes to replicate and confirm the present findings.
Sun W, Tu S Medicine (Baltimore). 2025; 104(10):e41497.
PMID: 40068062 PMC: 11903030. DOI: 10.1097/MD.0000000000041497.
Lou P, Huang Y, Li H, Zhao F, Xu J, Wang K BMC Cancer. 2025; 25(1):425.
PMID: 40065226 PMC: 11892260. DOI: 10.1186/s12885-025-13805-w.
Zebularine showed anti-tumor efficacy in clear cell renal cell carcinoma.
Xu H, Peng S, Li J, Bai Y, Zhao G, Liang S Front Pharmacol. 2025; 16:1531056.
PMID: 40028163 PMC: 11868290. DOI: 10.3389/fphar.2025.1531056.
Chen W, Miao J, Chen J, Chen J J Ovarian Res. 2025; 18(1):1.
PMID: 39754246 PMC: 11697806. DOI: 10.1186/s13048-024-01583-1.
Sun H, Liu S, Wei C Diabetol Metab Syndr. 2024; 16(1):309.
PMID: 39710725 PMC: 11665249. DOI: 10.1186/s13098-024-01557-9.